In vitro and in vivo activities of novel cyclic lipopeptides against staphylococcal biofilms

Protein and Peptide Letters

Volumn 21, Issue 4, 2014, Pages 352-356

  Bionda, Nina ^a   Pastar, Irena ^b   Davis, Stephen C ^b   Cudic, Predrag ^a  

^a TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotics; Biofilm; Cyclic lipopeptides; Eradication; Fusaricidins LI Fs; MRSA; Porcine model; Wound

Indexed keywords

CYCLODEPSIPEPTIDE; DAPTOMYCIN; PSEUDOMONIC ACID; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BIOFILM; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG STRUCTURE; ERADICATION THERAPY; FEMALE; GROWTH INHIBITION; IN VITRO STUDY; IN VIVO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SWINE;

AMINO ACID SEQUENCE; ANIMALS; ANTI-BACTERIAL AGENTS; BIOFILMS; LIPOPEPTIDES; MICROBIAL SENSITIVITY TESTS; PEPTIDES, CYCLIC; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; SWINE; WOUND HEALING;

EID: 84896326517     PISSN: 09298665     EISSN: None     Source Type: Journal    
DOI: 10.2174/09298665113206660101     Document Type: Article

References (51)

1. Lipsitch, M. The rise and fall of antimicrobial resistance. Trends Microbiol., 2011, 9, 438-444.
2. Costerton, J.W.; Stewart, P.S.; Greenberg, E.P. Bacterial bioflms: a common cause of persistent infections. Science, 1999, 284, 1318-1322.
3. Fluit, A.C.;Schmitz, F.J.;Verhoef, J. Multi-resistance to antimicrobial agents for the ten most frequently isolated bacterial pathogens. Int. J. Antimicrob. Agents, 2001, 18, 147-160.
4. Donlan, R.M. Biofilm formation: a clinically relevant microbiological process, Clin. Infect. Dis., 2001, 33, 1387-1392.
5. Ceri, H.; Olson, M.E.; Stremick, C.; Read, R.R.; Morck, D.; Buret, A. The Calgary Biofilm Device: New technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J. Clin. Microbiol., 1999, 37, 1771-1776.
6. Rodriguez-Martinez, J.M.; Pascual, A. Antimicrobial resistance in bacterial biofilms. Rev. Med. Microbiol., 2006, 17, 65-75.
7. Mah, T.F.;O'Toole, G.A. Mechanisms of biofilm resistance to antimicrobial agents, Trends Microbiol., 2001, 9, 34-39.
8. James, G. A.; Swogger, E.; Wolcott, R.; Pulcini, E.; Secor, P.; Sestrich, J.; Costerton, J. W.; Stewart, P.S. Biofilms in chronic wounds. Wound Repair Regen., 2008, 16, 37-44.
9. Falagas, M.E.; Kapaskelis, A.M.; Kouranos, V.D.; Kakisi, O.K.; Athanassa, Z.; Karageorgopoulos, D.E. Outcome of antimicrobial therapy in documented biofilm-associated infections: a review of the available clinical evidence. Drugs, 2009, 69, 1351-1361.
10. Davies, D. Understanding biofilm resistance to antibacterial agents, Nat. Rev. Drug Discov., 2003, 2, 114-122.
11. Bionda, N.; Cudic, P. Cyclic lipodepsipeptides in novel antimicrobial drug discovery. Croat. Chem. Acta, 2011, 84, 315-329.
12. Giuliani, A.; Pirri, G.P.; Nicoletto, S.F. Antimicrobial peptides: an overview of a promising class of therapeutics. Cent. Eur. J. Biol., 2007, 2, 1-33.
13. Roongsawang, N.; Washio, K.; Morikawa, M. Diversity of nonribosomal peptide synthetases involved in the biosynthesis of lipopeptide biosurfactants. Int. J. Molec. Sci., 2010, 12, 141-172.
14. Woodford, N. Novel agents for the treatment of resistant Grampositive infections. Expert Opin. Investig. Drugs, 2003, 12, 117-137.
15. Kern, W.V. Daptomycin: first in a new class of antibiotics for complicated skin and soft-tissue infections. Int. J. Clin. Pract., 2006, 60, 370-378.
16. Vilhena, C.; Bettencourt, A. Daptomycin: a review of properties, clinical use, drug delivery and resistance. Mini Rev. Med. Chem., 2012, 12, 202-209.
17. Arbeit, R.D.; Maki, D.; Tally, F.P.; Campanaro, E.; Eisenstein, B.I. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections, Clin. Infec. Dis., 2004, 38, 1673-1681.
18. Fowler, V.G.; Boucher, H.W.; Corey, G.R.; Abrutyn, E.; Karchmer, A.W.; Rupp, M.E.; Levine, D.P.; Chambers, H.F.; Tally, F.P.; Vigliani, G.A.; Cabell, C.H.; Link, A.S.; DeMeyer, I.; Filler, S.G.; Zervos, M.; Cook, P.; Parsonnet, J.; Bernstein, J.M.; Price, C.S.; Forrest, G.N.; Fätkenheuer, G.; Gareca, M.; Rehm, S.J.; Brodt, H.R.; Tice, A.; Cosgrove, S.E. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. New Engl. J. Med., 2006, 355, 653-665.
19. Lakey, J.H.; Maget-Dana, R.; Ptak, M. The lipopeptide antibiotic A21978C has a specific interaction with DMPC only in the presence of calcium ions. Biochim. Biophys. Acta, 1989, 985, 60-66.
20. Jung, D.; Rozek, A.; Okon, M.; Hancock, R.E.W. Structural transitions as determinants of the action of the calcium-dependent antibiotic daptomycin. Chem. Biol., 2004, 11, 949-957.
21. Hill, J.; Siedlecki, J.; Parr, I.; Morytko, M.; Yu, X.; Zhang, Y.; Silverman, J.; Controneo, N.; Laganas, V.; Li, T.; Lai, J.-J.; Keith, D.; Shimer, G.; Finn, J. Synthesis and biological activity of Nacylated ornithine analogues of daptomycin, Bioorg. Med. Chem. Lett., 2003, 13, 4187-4191.
22. Hobbs, J.K.; Miller, K.; O'Neill, A.J.; Chopra, I. Consequences of daptomycin-mediated membrane damage in Staphylococcus aureus. J. Antimicrob. Chemoth., 2008, 62, 1003-1008.
23. Silverman, J.A.; Perlmutter, N.G.; Shapiro, H.M. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus, Antimicrob. Agents Chemother., 2003, 47, 2538-2544.
24. Chan Tompkins, N.H.; Harnicar, S.J. Prescribing trends with daptomycin (cubicin) for the treatment of Gram-positive infections. P.T., 2008, 33, 282-288.
25. Tran, T.T.; Jaijakul, S.; Lewis, C.T.; Diaz, L.; Panesso, D.; Kaplan, H.B.; Murray, B.E.; Wanger, A.; Arias, C.A. Native valve endocarditis caused by Corynebacterium striatum with heterogeneous high-level daptomycin resistance: collateral damage from daptomycin therapy?. Antimicrob. Agents Chemother., 2012, 56, 3461-3464.
26. Boyle-Vavra, S.; Jones, M.; Gourley, B.L.; Holmes, M.; Ruf, R.; Balsam, A.R.; Boulware, D.R.; Kline, S.; Jawahir, S.; Devries, A.; Peterson, S.N.; Daum, R.S. Comparative genome sequencing of an isogenic pair of USA800 clinical methicillin-resistant Staphylococcus aureus isolates obtained before and after daptomycin treatment failure. Antimicrob. Agents Chemother., 2011, 55, 2018-2025.
27. Arias, C.A.; Panesso, D.; McGrath, D.M.; Qin, X.; Mojica, M.F.; Miller, C.; Diaz, L.; Tran, T.T.; Rincon, S.; Barbu, E.M.; Reyes, J.; Roh, J.H.; Lobos, E.; Sodergren, E.; Pasqualini, R.; Arap, W.; Quinn, J.P.; Shamoo, Y.; Murray, B.E.; Weinstock, G.M. Genetic basis for in vivo daptomycin resistance in enterococci. New Engl. J. Med., 2011, 365, 892-900.
28. Nadrah, K.; Strle, F. Antibiotic combinations with daptomycin for treatment of Staphylococcus aureus infections. Chemother. Res. Pract., 2011, 2011, 619321.
29. Kurusu, K.; Ohba, K. New peptide antibiotics LI-F03, F04, F05, F07, and F08, produced by Bacillus polymyxa. I. Isolation and characterization. J. Antibiot., 1987, 40, 1506-1514.
30. Kajimura, Y.; Kaneda, M.; Fusaricidin A. a new depsipeptide antibiotic produced by Bacillus polymyxa KT-8. Taxonomy, fermentation, isolation, structure elucidation and biological activity. J. Antibiot., 1996, 49, 129-135.
31. Kajimura, Y.; Kaneda, M.; Fusaricidins, B.C.D. new depsipeptide antibiotics produced by Bacillus polymyxa KT-8: isolation, structure elucidation and biological activity. J. Antibiot., 1997, 50, 220-228.
32. Kuroda, J.; Fukai, T.; Konishi, M.; Uno, J.; Kurusu, K.; Nomura, T. LI-F antibiotics, a family of antifungal cyclic depsipeptides produced by Bacillus polymyxa L-1129 Heterocyclesi, 2000, 53, 1533-1549.
33. Bionda, N.; Stawikowski, M.; Stawikowska, R.; Cudic, M.; Lopez-Vallejo, F.; Treitl, D.; Medina-Franco, J.; Cudic, P. Effects of cyclic lipodepsipeptide structural modulation on stability, antibacterial activity, and human cell toxicity. ChemMedChem, 2012, 7, 871-882.
34. Bionda, N.; Pitteloud, J.P.; Cudic, P. Solid-phase synthesis of fusaricidin/LI-F class of cyclic lipopeptides: Guanidinylation of resin-bound peptidyl amines. Biopolymers, 2013, 100, 160-166.
35. Stawikowski, M.; Cudic, P. A novel strategy for the solid-phase synthesis of cyclic lipodepsipeptides. Tetrahedron Lett., 2006, 47, 8587-8590.
36. Olson, M.E.; Ceri, H.; Morck, D.W.; Buret, A.G.; Read R.R. Biofilm bacteria: formation and comparative susceptibility to antibiotics. Can. J. Vet. Res., 2002, 66, 86-92.
37. Sepandj, F.; Ceri, H.; Gibb, A.; Read, R.; Olson, M. Minimum inhibitory concentration (MIC) versus minimum biofilm eliminating concentration (MBEC) in evaluation of antibiotic sensitivity of gram-negative bacilli causing peritonitis. Periton. Dialysis Int., 2004, 24, 65-67.
38. CLSI, Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically., Wayne, PA (USA), 2011.
39. Pastar, I.; Nusbaum, A.G.; Gil, J.; Patel, S.B.; Chen, J.; Valdes, J.; Stojadinovic, O.; Plano, L.R.; Tomic-Canic, M.; Davis, S.C. Interactions of methicillin resistant Staphylococcus aureus USA300 and Pseudomonas aeruginosa in polymicrobial wound infection. PloS ONE, 2013, 8, e56846.
40. Martineau, L.; Davis, S.C.; Peng, H.T.; Hung, A. Controlling methicillin resistant Staphyloccocus aureus and Pseudomonas aeruginosa wound infections with a novel biomaterial, J. Investig. Surg., 2007, 20, 217-227.
41. Pechter, P.M.; Gil, J.; Valdes, J.; Tomic-Canic, M.; Pastar, I.; Stojadinovic, O.; Kirsner, R.S.; Davis, S.C. Keratin dressings speed epithelialization of deep partial-thickness wounds, Wound Repair Regen., 2012, 20, 236-242.
42. King, M.D.; Humphrey, B.J.; Wang, Y.F.; Kourbatova, E.V.; Ray, S.M.; Blumberg, H.M. Emergence of community-acquired methicillin- resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann. Intern. Med., 2006, 144, 309-317.
43. Davis, S.C.; Ricotti, C.; Cazzaniga, A.; Welsh, E.; Eaglstein, W.H.; Mertz, P.M. Microscopic and physiologic evidence for biofilmassociated wound colonization in vivo, Wound Repair Regen., 2008, 16, 23-29.
44. Raad, I.; Hanna, H.; Jiang, Y.; Dvorak, T.; Reitzel, R.; Chaiban, G.; Sherertz, R.; Hachem, R. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillinresistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob. Agents Chemother., 2007, 51, 1656-1660.
45. Parra-Ruiz, J.; Vidaillac, C.; Rose, W.E.; Rybak, M.J. Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm. Antimicrob. Aents Chemother., 2010, 54, 4329-4334.
46. El-Azizi, M.; Rao, S.; Kanchanapoom, T.; Khardori, N. In vitro activity of vancomycin, quinupristin/dalfopristin, and linezolid against intact and disrupted biofilms of staphylococci. Ann. Clin. Microbiol. Antimicrob., 2005, 4, 2.
47. Gander, S.; Hayward, K.; Finch, R. An investigation of the antimicrobial effects of linezolid on bacterial biofilms utilizing an in vitro pharmacokinetic model. J. Antimicrob. Chemother., 2002, 49, 301-308.
48. LaPlante, K.L.; Mermel, L.A. In vitro activity of daptomycin and vancomycin lock solutions on staphylococcal biofilms in a central venous catheter model. Nephrol. Dial. Transplant., 2007, 22, 2239-2246.
49. Parra-Ruiz, J.; Vidaillac, C.; Rybak, M.J. Macrolides and staphylococcal biofilms. Rev. Esp. Quimioter., 2012, 25, 10-16.
50. Bionda, N.; Fleeman, R.M.; Shaw, L.N.; Cudic, P. Effect of Ester to Amide or N-Methylamide Substitution on Bacterial Membrane Depolarization and Antibacterial Activity of Novel Cyclic Lipopeptides. ChemMedChem, 2013, [Epub ahead of print].
51. Baltch, A.L.; Ritz, W.J.; Bopp, L.H.; Michelsen, P.B.; Smith, R.P. Antimicrobial activities of daptomycin, vancomycin, and oxacillin in human monocytes and of daptomycin in combination with gentamicin and/or rifampin in human monocytes and in broth against Staphylococcus aureus. Antimicrob. Agents Chemother., 2007, 51, 1559-1562.